These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 23471647

  • 1. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals.
    Merger D, Tanguay C, Langlois E, Lefebvre M, Bussières JF.
    Int Arch Occup Environ Health; 2014 Apr; 87(3):307-13. PubMed ID: 23471647
    [Abstract] [Full Text] [Related]

  • 2. Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study.
    Berruyer M, Tanguay C, Caron NJ, Lefebvre M, Bussières JF.
    J Occup Environ Hyg; 2015 Apr; 12(2):87-94. PubMed ID: 25105559
    [Abstract] [Full Text] [Related]

  • 3. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 66 Canadian hospitals: A 2016 follow-up study.
    Roland C, Caron N, Bussières JF.
    J Occup Environ Hyg; 2017 Aug; 14(8):661-669. PubMed ID: 28574754
    [Abstract] [Full Text] [Related]

  • 4. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals.
    Poupeau C, Tanguay C, Caron NJ, Bussières JF.
    J Oncol Pharm Pract; 2018 Jan; 24(1):9-17. PubMed ID: 27799608
    [Abstract] [Full Text] [Related]

  • 5. Environmental contamination with methotrexate in Canadian community pharmacies.
    Merger D, Tanguay C, Langlois É, Lefebvre M, Bussières JF.
    J Am Pharm Assoc (2003); 2013 Jan; 53(4):423-6. PubMed ID: 23892817
    [Abstract] [Full Text] [Related]

  • 6. Environmental Contamination with Cyclophosphamide, Ifosfamide, and Methotrexate: A Study of 51 Canadian Centres.
    Janes A, Tanguay C, Caron NJ, Bussières JF.
    Can J Hosp Pharm; 2015 Jan; 68(4):279-89. PubMed ID: 26327701
    [Abstract] [Full Text] [Related]

  • 7. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device.
    Guillemette A, Langlois H, Voisine M, Merger D, Therrien R, Mercier G, Lebel D, Bussières JF.
    J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Surface contamination with ten antineoplastic drugs in 83 Canadian centers.
    Chauchat L, Tanguay C, Caron NJ, Gagné S, Labrèche F, Bussières JF.
    J Oncol Pharm Pract; 2019 Jul; 25(5):1089-1098. PubMed ID: 29726786
    [Abstract] [Full Text] [Related]

  • 10. Quantification of healthcare workers' exposure to cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil by 24-h urine assay: A descriptive pilot study.
    Palamini M, Dufour A, Therrien R, Delisle JF, Mercier G, Gagné S, Caron N, Bussières JF.
    J Oncol Pharm Pract; 2020 Dec; 26(8):1864-1870. PubMed ID: 32138611
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers.
    Delafoy C, Roussy C, Hudon AF, Cirtiu CM, Caron N, Bussières JF, Tanguay C.
    J Oncol Pharm Pract; 2023 Mar; 29(2):338-347. PubMed ID: 35018847
    [Abstract] [Full Text] [Related]

  • 13. Cross-sectional evaluation of surface contamination with 9 antineoplastic drugs in 93 Canadian healthcare centers: 2019 results.
    Palamini M, Gagné S, Caron N, Bussières JF.
    J Oncol Pharm Pract; 2020 Dec; 26(8):1921-1930. PubMed ID: 32114883
    [Abstract] [Full Text] [Related]

  • 14. Levels and risks of surface contamination by thirteen antineoplastic drugs in the Czech and Slovak hospitals and pharmacies.
    Doležalová L, Bláhová L, Kuta J, Hojdarová T, Kozáková Š, Bláha L.
    Environ Sci Pollut Res Int; 2022 Apr; 29(18):26810-26819. PubMed ID: 34855176
    [Abstract] [Full Text] [Related]

  • 15. Surface contamination with nine antineoplastic drugs in 109 canadian centers; 10 years of a monitoring program.
    Chabut C, Tanguay C, Gagné S, Caron N, Bussières JF.
    J Oncol Pharm Pract; 2022 Mar; 28(2):343-352. PubMed ID: 33567975
    [Abstract] [Full Text] [Related]

  • 16. Environmental contamination with hazardous drugs in quebec hospitals.
    Bussières JF, Tanguay C, Touzin K, Langlois E, Lefebvre M.
    Can J Hosp Pharm; 2012 Nov; 65(6):428-35. PubMed ID: 23288952
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 124 centers.
    Pinet E, Cirtiu CM, Caron N, Bussières JF, Tanguay C.
    J Oncol Pharm Pract; 2024 Jan; 30(1):19-29. PubMed ID: 37021440
    [Abstract] [Full Text] [Related]

  • 19. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital.
    Hedmer M, Tinnerberg H, Axmon A, Jönsson BA.
    Int Arch Occup Environ Health; 2008 Jul; 81(7):899-911. PubMed ID: 18066576
    [Abstract] [Full Text] [Related]

  • 20. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.
    Sessink PJ, Connor TH, Jorgenson JA, Tyler TG.
    J Oncol Pharm Pract; 2011 Mar; 17(1):39-48. PubMed ID: 20156932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.